Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 15 04:00PM ET
5.37
Dollar change
-0.31
Percentage change
-5.38
%
Index- P/E- EPS (ttm)-2.96 Insider Own13.66% Shs Outstand6.03M Perf Week-37.56%
Market Cap118.30M Forward P/E- EPS next Y- Insider Trans0.52% Shs Float5.21M Perf Month-42.11%
Income-14.77M PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-52.58%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-58.45%
Book/sh-0.48 P/B- EPS next Y- ROA-438.99% Short Interest- Perf Year-21.44%
Cash/sh0.17 P/C31.38 EPS next 5Y- ROE-2248.79% 52W Range5.61 - 18.50 Perf YTD-56.77%
Dividend Est.- P/FCF- EPS past 5Y-5.95% ROI- 52W High-70.97% Beta2.59
Dividend TTM- Quick Ratio1.50 Sales past 5Y0.00% Gross Margin- 52W Low-4.28% ATR (14)1.07
Dividend Ex-Date- Current Ratio1.50 EPS Y/Y TTM2.91% Oper. Margin0.00% RSI (14)32.81 Volatility10.24% 12.12%
Employees5 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price36.13
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q63.98% Payout- Rel Volume8.06 Prev Close5.68
Sales Surprise- EPS Surprise69.00% Sales Q/Q- EarningsNov 15 AMC Avg Volume11.94K Price5.37
SMA20-38.89% SMA50-43.90% SMA200-56.80% Trades Volume96,246 Change-5.38%
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McFadden Michael E.Chief Executive OfficerNov 13 '24Buy5.752,60814,99614,142Nov 15 04:23 PM
MERTZ LEONARD POWELLDirectorNov 13 '24Buy5.758,69549,99693,725Nov 15 04:19 PM
HAVENS JOHN PRENTISSDirectorNov 13 '24Buy5.754,34724,995273,272Nov 15 04:17 PM